Nicotine-induced Tumor Growth is decreased by BEL. by Lindsay E. Calderon (332344)

Piceatannol decreases renal fibrosis in the UUO kidney. by Sin Young Choi (3370778)

Supplementary Material for: Cardiac Troponin Is Elevated in Patients with Thyrotoxicosis and Decreases as Thyroid Function Improves and Brain Natriuretic Peptide Levels Decrease by Watanabe N. (4118812)

“…Of the 27 patients with elevated hsTnI (≥5.0 pg/mL), the hsTnI level was normalized in 20 patients within a year. …”

T198A/G substitution markedly decrease p27 protein stability. by Monica Schiappacassi (227672)

PV1-treated mice exhibited a decrease in overall activation of T lymphocytes. by Pedro Henrique Papotto (791904)

Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study by Asita Wongprikorn (2837378)

“…At 12 weeks of treatment with pitavastatin compared to placebo; mean [95% confidence interval (CI)] total cholesterol (TC) was 207 (187.3, 226.8) mg/dL vs 246.3 (226.5, 266) mg/dL (<i>p</i> <0.001); mean (95% CI) triglyceride (TG) was 351.3 (193.2, 509.4) mg/dL vs 279.1 (121, 437.2) mg/dL (<i>p</i> = 0.269); mean (95% CI) high density lipoprotein (HDL) was 45.3 (40.4, 50.2) mg/dL vs 44.2 (39.3, 49.1) mg/dL (<i>p</i> = 0.354); and mean (95% CI) low density lipoprotein (LDL) was 113.2 (100.4, 126) mg/dL vs 145.6 (132.8, 158.4) mg/dL (<i>p</i> <0.001). …”

Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo. by Rebecka Hellsten (348459)

“…<p>A. DU145 and LNCaP-IL6 cells were treated with galiellalactone (5–50 µM) for 24 h and subjected to ALDEFLUOR® assay. …”

Overexpression of PLIC-1 decreased Trif abundance in a Nocodazole-sensitive manner. by Nabanita Biswas (349647)

<i>btuE</i> expression results in decreased intracellular ROS. by Felipe A. Arenas (23050)

Longitudinal associations between baseline CVR and 2 years changes in BDI-II score in participants with a BDI-II score <18 in the PREDIMED-PLUS trial at baseline. by Sandra Martín-Peláez (11353470)

Subjects:

Association between cardiovascular risk and a) depressive status (BDI-II ≥18) and b) BDI-II score, in the PREDIMED-PLUS trial, stratified by CVR factors, at baseline. by Sandra Martín-Peláez (11353470)

Subjects:

%-change after 3 and 12 months of hormone therapy in trans women and trans men. by Moya H. Schutte (12245290)

Antitumor Activity of FGFR Inhibitor as a Result of a Decrease in the Breast TIC Subpopulation In Vivo. by Sungeun Kim (105743)

Effects of busulfan treatment (6 mg/kg) on the epididymis and sperm of mice over a three-week period. by Lingjun Zhao (21763122)

“…<p>(A) The epididymal sperm concentrations decrease over time and significantly differ between hour 0 (control) and day 21 (<i>n </i>= 3 per group). …”

Concentration of suspended solids (mg /l) in six concentrations of water turbidity. by Javier Manjarrez (531011)

The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years. by Regina C. R. M. Abdulkader (302450)

“…Metabolic syndrome: presence of at least three of the following criteria: a waist circumference ≥90 cm for men or ≥80 cm for women, triglycerides ≥150 mg/dL, an HDL cholesterol ≤40 mg/dL for males or ≤50 mg/dL for females, a systolic blood pressure ≥130 mm Hg or a diastolic blood pressure ≥85 mmHg and a fasting plasma glucose ≥100 mg/dL. …”

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

VGB decreased activation of the mTOR pathway in vivo. by Bo Zhang (6559)

Imatinib decreases <i>in vivo</i> proliferation of T-cells. by Ludovic Belle (293091)

FLZ decreased the expression of phospho-APP and APP-CTF. by Xiu-Qi Bao (479278)